These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33307996)

  • 1. Fatal intracranial haemorrhage in a hypertensive patient with atrial fibrillation and coronavirus disease 2019.
    Krzystanek E; Gawryluk J; Arkuszewski M
    Neuroradiol J; 2021 Apr; 34(2):147-150. PubMed ID: 33307996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
    Kirchhof P; Haas S; Amarenco P; Hess S; Lambelet M; van Eickels M; Turpie AGG; Camm AJ;
    J Am Heart Assoc; 2020 Mar; 9(5):e009530. PubMed ID: 32079476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
    Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
    Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Prospective Safety Analysis of Rivaroxaban.
    Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
    J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
    Li X; Zuo C; Ji Q; Xue Y; Wang Z; Lv Q
    Drug Des Devel Ther; 2021; 15():1931-1943. PubMed ID: 33986592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation.
    Deekonda P; Stokes OM; Chan D
    Eur Spine J; 2019 Apr; 28(4):688-692. PubMed ID: 27807780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
    Burgos KD; Sienko SE; Hoffman JL; Koerber JM; Smythe MA
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):372-378. PubMed ID: 28301906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
    Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of rivaroxaban associated intracranial hemorrhage.
    Lo JC; Gerona RR
    West J Emerg Med; 2014 Jul; 15(4):375-7. PubMed ID: 25035736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
    Barnett AS; Cyr DD; Goodman SG; Levitan BS; Yuan Z; Hankey GJ; Singer DE; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hacke W; Mahaffey KW; Nessel CC; Fox KAA; Patel MR; Piccini JP
    Int J Cardiol; 2018 Apr; 257():78-83. PubMed ID: 29506743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk.
    Hirayama A; Tanahashi N; Tachiiri M; Hayasaki T
    Circ J; 2022 Jun; 86(7):1204. PubMed ID: 35644537
    [No Abstract]   [Full Text] [Related]  

  • 19. JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk　- Reply.
    Ono K; Iwasaki YK; Shimizu W
    Circ J; 2022 Jun; 86(7):1205. PubMed ID: 35644538
    [No Abstract]   [Full Text] [Related]  

  • 20. Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation: A Prospective Magnetic Resonance Imaging Study.
    Gioia LC; Kate M; Sivakumar L; Hussain D; Kalashyan H; Buck B; Bussiere M; Jeerakathil T; Shuaib A; Emery D; Butcher K
    Stroke; 2016 Jul; 47(7):1917-9. PubMed ID: 27222524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.